Double approval from NICE increases NHS treatment options in England and Wales
The National Institute of Health and Care Excellence (NICE) has approved the myeloma treatment lenalidomide (Revlimid®) and dexamethasone for use in treating newly diagnosed patients and patients at first relapse. The decision means that lenalidomide and dexamethasone will now be available on the NHS to patients in England and Wales who are not eligible for…
Details